Biologic Tapering in axSpA: What Research Says and What it Means for Patients
Spondycast di The Spondylitis Association of America (SAA)
Note sull'episodio
Rheumatologist Dr. Marina Magrey discusses her latest research on biologic DMARD dose tapering in axial spondyloarthritis, outlining when it may be appropriate, its risks and benefits, and key considerations for patients.
Parole chiave
researchmedicationflaresbiologic taperingTNF Inhibitors